Affandi B. 1996. Personal communication.
Bhasin S et al. 1985. Hormonal effects of gonadotropin-releasing hormone
(GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH
agonist and androgen. J Clin Endocrinol Metab 60:998-1003.
Bhasin S et al. 1987. Hormonal effects of gonadotropin-releasing hormone
(GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and
androgen. J Clin Endocrinol Metab 65:568-574.
Centchroman. 1991. Multicentric trial with biweekly cum weekly dose.
Central Drug Research Institute.
Croxatto HB et al. 1987. Treatment with Norplant subdermal implants
inhibits sperm penetration through cervical mucus in vitro. Contraception 36(2):
193-201.
Darney PD et al. 1990. Sustained release contraceptives. Current
Problems in Obstetrics, Gynecology and Fertility 13(3): 152-160.
Davidson JM, M Kwan and WJ Greenleaf. 1982.Hormonal replacement and
sexuality in men Clinics Endocrinol Metab 11:599-623.
Davies GC and JA Norton. 1992. A review of the effects of long-acting
progestin-only contraceptives on ovarian activity. Advances in Contraception 8(1)
1-19.
Diaz S et al. 1987. Long-term follow-up of women treated with Norplant®
implants. Contraception 35(6): 551-567.
Goldzieher JW and VD Castracane. 1984. Antifertility effects of
progestational steriods in Endocrine Mechanisms in Fertility Regulation. Benagiano
G and Diczfalusy E (eds). Raven Press: New York, New York.
Guillebaud J. 1995. Norplant II clinical Expert Report. Courtesy
of Leiras Oy Pharmaceuticals.
Karten MJ and JE Rivier. 1986. Gonadotropin-releasing hormone analog
design. Structure-function studies toward the development of agonistsand antagonists:
rationale and perspective. Endocr Rev 7:44-46.
Linde R et al. 1982. Reversible inhibition of testcular steroidogenesis
and spermatogenesis by potent gonadotropin-releasing hormone agonist I normal men: an
aapproach toward the development of a male contraceptive. N Engl J Med 305:663-668.
Matsumoto AM. 1990. Effects of chronic testosterone administration in
normal men: safety and efficacy of high dosage testosterone and parallel dose-depended
suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J
Clin Endocrinol Metab 80:282-87.
Nityanand S et al. 1990. Clinical evaluation of Centchroman: a new oral
contraceptive, in Hormone Antagonists for Fertility Regulation. Puri CP and Van
Look, PFA (eds). ISSRF: Bombay, India.
Pangkahila W. 1991. Reversible azoospermia induced by an
androgen-progestin combination regimen in Indonesia men. International Journal of
Andrology. 14(4):248-256.
Population Council. 1990. Norplant levonorgestrel implants. A summary
of scientific data. The Population Council: New York.
Puri V et al. 1988. Results of multicentric trial of Centchroman, in Pharmacology
for Health in Asia. Dhawan, BN et al (eds). Allied Publishers: New Delhi, India.
Roy S et al. 1976. Induction of ovulation in the human with centchroman:
a preliminary report. Fertil and Steril 27(9): 1108-1110.
Singh MM et al. 1986. Effect of centchroman on tubal transport and
pre-implanatation embryonic development in rats. J Reprod Fertl 76:317-324.
Sivin I. 1988. International experience with NORPLANT® and
NORPLANT ® -2 contraception. Studies in Family Planning 19: 81-84.
Trussell J et al. 1990. A guide to interpreting contraceptive efficacy
studies. Obstetrics and Gynecology 76: 558-567.
World Health Organization Task Force on Methods for the Regulation of
Male Fertility. 1990. Contraceptive efficacy of testosterone-induced azoospermia in
normal men Lancet 336:872, 955-959.
